fluorouracil has been researched along with Fever in 47 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 9.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 9.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "Capecitabine is effective against metastatic breast cancer (MBC)." | 9.14 | Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. ( Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G, 2010) |
| "The aim of the study was to investigate the associations between UGT1A1(*)28 genotype and (1) response rates, (2) febrile neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan." | 9.13 | UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T, 2008) |
| "This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 9.11 | Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. ( Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004) |
| "Paclitaxel has significant antitumor activity in patients with metastaticbreast cancer who have been previously treated with or exposed to anthracycline-containing chemotherapy." | 9.10 | Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. ( Ames, F; Berry, D; Booser, DJ; Buzdar, AU; Frye, DK; Holmes, FA; Hortobagyi, GN; Hoy, E; Hunt, K; Ibrahim, NK; Kau, SW; Manuel, N; McNeese, MD; Rahman, Z; Rivera, E; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Thomas, E; Valero, V; Walters, R, 2002) |
| "In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL)." | 9.09 | Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. ( de Vries, EG; Hospers, GA; Mulder, NH; Schröder, CP; Sleijfer, DT; van der Graaf, WT; Willemse, PH, 1999) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 9.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "The aim of this study was to investigate the association of two genetic polymorphisms, MDM2 SNP309 and TP53 R72P, with incidence of neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide (FEC)." | 7.78 | MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. ( Kim, SJ; Maruyama, N; Nakayama, T; Noguchi, S; Okishiro, M; Shimazu, K; Shimomura, A; Tamaki, Y; Tsunashima, R, 2012) |
| "The risk of treatment-related death (TRD) and febrile neutropaenia (FN) with adjuvant taxane- based chemotherapy for early breast cancer is unknown in Malaysia despite its widespread usage in recent years." | 7.78 | Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting. ( Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM, 2012) |
| " We evaluated the efficacy of a combined antibiotic regimen of monobactam (aztreonam) and antipseudomonal penicillin (piperacillin) in treating neutropenic fever episodes in gynecologic-oncology patients receiving cisplatin-based chemotherapy." | 7.70 | Aztreonam plus piperacillin--empiric treatment of neutropenic fever in gynecology-oncology patients receiving cisplatin-based chemotherapy. ( Altaras, M; Beyth, Y; Chowers, M; Fishman, A; Lang, R, 1998) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 5.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 5.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 5.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "Capecitabine is effective against metastatic breast cancer (MBC)." | 5.14 | Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. ( Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G, 2010) |
| "Adding irinotecan and/or oxaliplatin to every-2-week 5-fluorouracil (5-FU)/leucovorin (LV) prolongs survival in patients with colorectal cancer (CRC) but increases neutropenia frequency." | 5.14 | A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. ( Dreiling, L; Gollard, R; Hecht, JR; Heim, W; Malik, I; Mo, M; Patel, R; Pillai, M; Swan, F, 2010) |
| "The aim of the study was to investigate the associations between UGT1A1(*)28 genotype and (1) response rates, (2) febrile neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan." | 5.13 | UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T, 2008) |
| "This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 5.11 | Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. ( Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004) |
| "The authors present the Hungarian interim analysis and experience with the BCIRG 001 randomized, multicentric, phase III clinical trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) and FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients." | 5.10 | [Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial]. ( Boér, K; Juhos, E; Láng, I; Pintér, T; Szántó, J, 2003) |
| "Paclitaxel has significant antitumor activity in patients with metastaticbreast cancer who have been previously treated with or exposed to anthracycline-containing chemotherapy." | 5.10 | Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. ( Ames, F; Berry, D; Booser, DJ; Buzdar, AU; Frye, DK; Holmes, FA; Hortobagyi, GN; Hoy, E; Hunt, K; Ibrahim, NK; Kau, SW; Manuel, N; McNeese, MD; Rahman, Z; Rivera, E; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Thomas, E; Valero, V; Walters, R, 2002) |
| "In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL)." | 5.09 | Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. ( de Vries, EG; Hospers, GA; Mulder, NH; Schröder, CP; Sleijfer, DT; van der Graaf, WT; Willemse, PH, 1999) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 5.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "Variable febrile neutropenia (FN) rates reported with adjuvant TC (taxotere®, cyclophosphamide) and FEC-D (5-flurouracil, epirubicin, cyclophosphamide, docetaxel) outside of clinical trials have precluded definitive recommendations for primary G-CSF (granulocyte colony-stimulating factor) prophylaxis in most jurisdictions." | 4.88 | Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. ( Rayson, D; Thompson, K; Younis, T, 2012) |
| "The risk of treatment-related death (TRD) and febrile neutropaenia (FN) with adjuvant taxane- based chemotherapy for early breast cancer is unknown in Malaysia despite its widespread usage in recent years." | 3.78 | Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting. ( Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM, 2012) |
| "The aim of this study was to investigate the association of two genetic polymorphisms, MDM2 SNP309 and TP53 R72P, with incidence of neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide (FEC)." | 3.78 | MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. ( Kim, SJ; Maruyama, N; Nakayama, T; Noguchi, S; Okishiro, M; Shimazu, K; Shimomura, A; Tamaki, Y; Tsunashima, R, 2012) |
| "We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| " We evaluated the efficacy of a combined antibiotic regimen of monobactam (aztreonam) and antipseudomonal penicillin (piperacillin) in treating neutropenic fever episodes in gynecologic-oncology patients receiving cisplatin-based chemotherapy." | 3.70 | Aztreonam plus piperacillin--empiric treatment of neutropenic fever in gynecology-oncology patients receiving cisplatin-based chemotherapy. ( Altaras, M; Beyth, Y; Chowers, M; Fishman, A; Lang, R, 1998) |
| "Patients with stage II and III esophageal cancer were enrolled." | 2.77 | Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. ( Chak, A; Chang, KJ; Hanna, N; Pinto, H; Reid, T; Senzer, N; Soetikno, R; Swisher, S, 2012) |
| "To evaluate the efficacy and safety of high doses of thymopentin (10 mg/d) combined with transartery chemoembolization for primary liver cancer." | 2.73 | [Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer]. ( Li, T; Li, ZW; Wen, HC, 2007) |
| " This study was to compare effects and toxicities of intratumoral H101 injection combined with cisplatin plus 5-fluorouracil (PF) regimen or adriamycin plus 5-fluorouracil (AF) regimen versus PF or AF regimen alone in treating patients with head and neck or esophagus squamous cell cancer." | 2.71 | [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. ( Chang, JH; Chen, JC; Chen, ZC; Fan, QX; Guan, ZZ; Hu, XH; Huang, JJ; Jiang, WQ; Liu, JW; Lu, JW; Wang, HQ; Wu, GH; Xia, ZJ; Zhang, L; Zhang, Y; Zheng, X; Zhou, QH, 2004) |
| " This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds." | 2.69 | A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. ( Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J, 2000) |
| "Grade 3 infections were seen in 9 cycles (5%)." | 2.67 | Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. ( Chevallier, B; Chollet, P; Hurteloup, P; Olivier, JP; Roche, H, 1993) |
| " Oral administration of uridine has also been studied, but bioavailability was low." | 2.38 | Modulation of fluorouracil toxicity with uridine. ( Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1992) |
| "436 patients with unresectable pancreatic cancers received HIFU treatment; the other 253 patients received non-HIFU treatment." | 1.43 | A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. ( Chen, QW; Cheng, CS; Meng, ZQ; Ning, ZY; Shi, WD; Song, LB; Wang, K; Wang, P; Xie, J; Xu, LT; Zhang, CY; Zhu, XY; Zhuang, LP, 2016) |
| "Furthermore, the ovarian cancer infiltrating the sigmoid colon gave distant metastasis in the coecum, too." | 1.42 | [Individualized therapy of synchronous ovarian and colon cancers with lymph]. ( Bishr, AM; Deme, D; Nizar, J; Telekes, A, 2015) |
| "First, HT-29 colon cancer cells were cultured in vitro as spheroids with a mean diameter of 100 µm." | 1.42 | Role of iron oxide core of polymeric nanoparticles in the thermosensitivity of colon cancer cell line HT-29. ( Esmaelbeygi, E; Eynali, S; Khoee, S; Khoei, S, 2015) |
| " Under the condition of adding 5-FU at various concentrations for 24 hours, the uptake rate of (18)F-FDG was negatively correlated with 5-FU dosage (r = -0." | 1.38 | Early evaluation for treatment efficacy of 5-fluorouracil and hyperthermia on HCT-116 colon cancer cells by fluorine-18-fluorodeoxyglucose uptake. ( Chen, SJ; Deng, SM; Wang, ZX; Zhang, B, 2012) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 1.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.26) | 18.7374 |
| 1990's | 11 (23.40) | 18.2507 |
| 2000's | 16 (34.04) | 29.6817 |
| 2010's | 16 (34.04) | 24.3611 |
| 2020's | 2 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Copur, MS | 1 |
| Schroeder, CW | 1 |
| Ly, Q | 1 |
| Wedel, W | 1 |
| Kelly, JR | 1 |
| Rodriguez, P | 1 |
| Tun, SM | 1 |
| Lintel, N | 1 |
| Horn, AJ | 1 |
| Riley, B | 1 |
| Saito, S | 1 |
| Yanagisawa, R | 1 |
| Minami, K | 1 |
| Uchida, E | 1 |
| Watanabe, T | 1 |
| Komori, K | 1 |
| Kurata, T | 1 |
| Nakamura, T | 1 |
| Sakashita, K | 1 |
| Schad, F | 1 |
| Atxner, J | 1 |
| Buchwald, D | 1 |
| Happe, A | 1 |
| Popp, S | 1 |
| Kröz, M | 1 |
| Matthes, H | 1 |
| Esmaelbeygi, E | 1 |
| Khoei, S | 1 |
| Khoee, S | 1 |
| Eynali, S | 1 |
| Deme, D | 1 |
| Bishr, AM | 1 |
| Nizar, J | 1 |
| Telekes, A | 1 |
| Ning, ZY | 1 |
| Cheng, CS | 1 |
| Xie, J | 1 |
| Chen, QW | 1 |
| Xu, LT | 1 |
| Zhuang, LP | 1 |
| Zhang, CY | 1 |
| Song, LB | 1 |
| Shi, WD | 1 |
| Zhu, XY | 1 |
| Wang, P | 1 |
| Wang, K | 1 |
| Meng, ZQ | 1 |
| Kweekel, DM | 1 |
| Gelderblom, H | 1 |
| Van der Straaten, T | 1 |
| Antonini, NF | 1 |
| Punt, CJ | 1 |
| Guchelaar, HJ | 1 |
| Bajetta, E | 1 |
| Di Bartolomeo, M | 1 |
| Buzzoni, R | 1 |
| Ferrario, E | 1 |
| Dotti, KF | 1 |
| Mariani, L | 1 |
| Bajetta, R | 1 |
| Gevorgyan, A | 1 |
| Venturino, P | 1 |
| Galassi, M | 1 |
| Rondina, MT | 1 |
| Fang, JC | 1 |
| Yu, M | 1 |
| Nieto, Y | 1 |
| Aramendía, JM | 1 |
| Espinós, J | 1 |
| De la Cruz, S | 1 |
| Fernández-Hidalgo, O | 1 |
| Santisteban, M | 1 |
| Arbea, L | 1 |
| Aristu, J | 1 |
| Martínez-Monge, R | 1 |
| Moreno, M | 1 |
| Pina, L | 1 |
| Sola, J | 1 |
| Zornoza, G | 1 |
| Regueira, FM | 1 |
| Ozdemir, NY | 1 |
| Abali, H | 1 |
| Oksüzoğlu, B | 1 |
| Budakoglu, B | 1 |
| Uncu, D | 1 |
| Güler, T | 1 |
| Odabaşi, H | 1 |
| Zengin, N | 1 |
| Hecht, JR | 1 |
| Pillai, M | 1 |
| Gollard, R | 1 |
| Heim, W | 1 |
| Swan, F | 1 |
| Patel, R | 1 |
| Dreiling, L | 1 |
| Mo, M | 1 |
| Malik, I | 1 |
| Schønnemann, KR | 1 |
| Yilmaz, M | 1 |
| Andersen, M | 1 |
| Pfeiffer, P | 1 |
| Okishiro, M | 1 |
| Kim, SJ | 1 |
| Tsunashima, R | 1 |
| Nakayama, T | 1 |
| Shimazu, K | 1 |
| Shimomura, A | 1 |
| Maruyama, N | 1 |
| Tamaki, Y | 1 |
| Noguchi, S | 1 |
| Huang, CE | 1 |
| Lu, CH | 1 |
| Chen, PT | 1 |
| Chan, CH | 1 |
| Chen, WC | 1 |
| Wang, WH | 1 |
| Wu, JY | 1 |
| Kuan, FC | 1 |
| Lee, KD | 1 |
| Chen, CC | 1 |
| Younis, T | 1 |
| Rayson, D | 1 |
| Thompson, K | 1 |
| Wang, ZX | 1 |
| Zhang, B | 1 |
| Deng, SM | 1 |
| Chen, SJ | 1 |
| Chang, KJ | 1 |
| Reid, T | 1 |
| Senzer, N | 1 |
| Swisher, S | 1 |
| Pinto, H | 1 |
| Hanna, N | 1 |
| Chak, A | 1 |
| Soetikno, R | 1 |
| Karachaliou, N | 1 |
| Ziras, N | 1 |
| Syrigos, K | 1 |
| Tryfonidis, K | 1 |
| Papadimitraki, E | 1 |
| Kontopodis, E | 1 |
| Bozionelou, V | 1 |
| Kalykaki, A | 1 |
| Georgoulias, V | 1 |
| Mavroudis, D | 1 |
| Sargen, M | 1 |
| Wanat, KA | 1 |
| Jambusaria, A | 1 |
| Rosenbach, M | 1 |
| Sobanko, J | 1 |
| Miller, CJ | 1 |
| Phua, CE | 1 |
| Bustam, AZ | 1 |
| Yusof, MM | 1 |
| Saad, M | 1 |
| Yip, CH | 1 |
| Taib, NA | 1 |
| Ng, CH | 1 |
| Teh, YC | 1 |
| Osterlund, P | 1 |
| Orpana, A | 1 |
| Elomaa, I | 1 |
| Repo, H | 1 |
| Joensuu, H | 1 |
| Bocci, G | 1 |
| Danesi, R | 1 |
| Allegrini, G | 1 |
| Innocenti, F | 1 |
| Di Paolo, A | 1 |
| Falcone, A | 1 |
| Conte, PF | 1 |
| Del Tacca, M | 1 |
| Boér, K | 1 |
| Láng, I | 1 |
| Juhos, E | 1 |
| Pintér, T | 1 |
| Szántó, J | 1 |
| Stippel, DL | 1 |
| Töx, U | 1 |
| Gossmann, A | 1 |
| Beckurts, KT | 1 |
| Hölscher, AH | 1 |
| Sørbye, H | 1 |
| Glimelius, B | 1 |
| Berglund, A | 1 |
| Fokstuen, T | 1 |
| Tveit, KM | 1 |
| Braendengen, M | 1 |
| Øgreid, D | 1 |
| Dahl, O | 1 |
| Xia, ZJ | 1 |
| Chang, JH | 1 |
| Zhang, L | 1 |
| Jiang, WQ | 1 |
| Guan, ZZ | 1 |
| Liu, JW | 1 |
| Zhang, Y | 1 |
| Hu, XH | 1 |
| Wu, GH | 1 |
| Wang, HQ | 1 |
| Chen, ZC | 1 |
| Chen, JC | 1 |
| Zhou, QH | 1 |
| Lu, JW | 1 |
| Fan, QX | 1 |
| Huang, JJ | 1 |
| Zheng, X | 1 |
| Lee, A | 1 |
| Ezzeldin, H | 1 |
| Fourie, J | 1 |
| Diasio, R | 1 |
| Pérez, J | 1 |
| Rodríguez, MJ | 1 |
| Campaña, O | 1 |
| Veiras, S | 1 |
| Lorenzo, D | 1 |
| Lamas, M | 1 |
| Alvarez, J | 1 |
| Li, T | 1 |
| Li, ZW | 1 |
| Wen, HC | 1 |
| Koga, S | 1 |
| Izumi, A | 1 |
| Maeta, M | 1 |
| Shimizu, N | 1 |
| Osaki, Y | 1 |
| Kanayama, H | 1 |
| Kusama, M | 1 |
| Tominaga, T | 1 |
| Enomoto, K | 1 |
| Yoshida, M | 1 |
| Koyama, H | 1 |
| Sonoo, H | 1 |
| Takashima, S | 1 |
| Abe, R | 1 |
| Nishi, T | 1 |
| Yamaguchi, S | 1 |
| Chevallier, B | 1 |
| Roche, H | 1 |
| Olivier, JP | 1 |
| Chollet, P | 1 |
| Hurteloup, P | 1 |
| Klostergaard, J | 1 |
| Leroux, ME | 1 |
| Hsu, HA | 1 |
| Hsi, BP | 1 |
| Siddik, ZH | 1 |
| Danhauser, LL | 1 |
| Tomasovi, SP | 1 |
| Dranitsaris, G | 1 |
| Tran, TM | 1 |
| Ichikawa, D | 1 |
| Yamaguchi, T | 1 |
| Shirasu, M | 1 |
| Kitamura, K | 1 |
| Inazawa, J | 1 |
| Abe, T | 1 |
| Takahashi, T | 1 |
| Rougier, P | 1 |
| Bugat, R | 1 |
| Douillard, JY | 1 |
| Culine, S | 1 |
| Suc, E | 1 |
| Brunet, P | 1 |
| Becouarn, Y | 1 |
| Ychou, M | 1 |
| Marty, M | 1 |
| Extra, JM | 1 |
| Bonneterre, J | 1 |
| Adenis, A | 1 |
| Seitz, JF | 1 |
| Ganem, G | 1 |
| Namer, M | 1 |
| Conroy, T | 1 |
| Negrier, S | 1 |
| Merrouche, Y | 1 |
| Burki, F | 1 |
| Mousseau, M | 1 |
| Herait, P | 1 |
| Mahjoubi, M | 1 |
| Sanz-Altamira, PM | 1 |
| Spence, LD | 1 |
| Huberman, MS | 1 |
| Posner, MR | 1 |
| Steele, G | 1 |
| Perry, LJ | 1 |
| Stuart, KE | 1 |
| Fishman, A | 1 |
| Chowers, M | 1 |
| Altaras, M | 1 |
| Beyth, Y | 1 |
| Lang, R | 1 |
| Schröder, CP | 1 |
| de Vries, EG | 1 |
| Mulder, NH | 1 |
| Willemse, PH | 1 |
| Sleijfer, DT | 1 |
| Hospers, GA | 1 |
| van der Graaf, WT | 1 |
| Asanami, S | 1 |
| Shimono, K | 1 |
| Pronk, LC | 1 |
| Vasey, P | 1 |
| Sparreboom, A | 1 |
| Reigner, B | 1 |
| Planting, AS | 1 |
| Gordon, RJ | 1 |
| Osterwalder, B | 1 |
| Verweij, J | 1 |
| Twelves, C | 1 |
| Santini, D | 1 |
| Tonini, G | 1 |
| Salerno, A | 1 |
| Vincenzi, B | 1 |
| Patti, G | 1 |
| Battistoni, F | 1 |
| Dicuonzo, G | 1 |
| Labianca, R | 1 |
| Olencki, T | 1 |
| Peereboom, D | 1 |
| Wood, L | 1 |
| Budd, GT | 1 |
| Novick, A | 1 |
| Finke, J | 1 |
| McLain, D | 1 |
| Elson, P | 1 |
| Bukowski, RM | 1 |
| Buzdar, AU | 1 |
| Singletary, SE | 1 |
| Valero, V | 1 |
| Booser, DJ | 1 |
| Ibrahim, NK | 1 |
| Rahman, Z | 1 |
| Theriault, RL | 1 |
| Walters, R | 1 |
| Rivera, E | 1 |
| Smith, TL | 1 |
| Holmes, FA | 1 |
| Hoy, E | 1 |
| Frye, DK | 1 |
| Manuel, N | 1 |
| Kau, SW | 1 |
| McNeese, MD | 1 |
| Strom, E | 1 |
| Thomas, E | 1 |
| Hunt, K | 1 |
| Ames, F | 1 |
| Berry, D | 1 |
| Hortobagyi, GN | 1 |
| van Groeningen, CJ | 1 |
| Peters, GJ | 1 |
| Pinedo, HM | 1 |
| Fain, WR | 1 |
| Conn, JH | 1 |
| Chavez, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer[NCT00094809] | Phase 2 | 252 participants (Actual) | Interventional | 2003-02-01 | Completed | ||
| A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer[NCT00051480] | Phase 2 | 0 participants | Interventional | Completed | |||
| The Application of Novel Oncolytic Virus in Late Stage Solid Tumors[NCT06080984] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-10-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 2 |
| Placebo | 8 |
Dose delay or reduction in chemotherapy doses due to neutropenia (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 5 |
| Placebo | 26 |
Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 41 |
| Placebo | 53 |
Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC < 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 3 |
| Placebo | 10 |
Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) < 1 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 16 |
| Placebo | 51 |
Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) <0.5 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 13 |
| Placebo | 17 |
Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of neutropenia (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 7 |
| Placebo | 9 |
Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 34 |
| Placebo | 37 |
Kaplan-Meier estimate of the median time to disease progression or death (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment
| Intervention | Days (Median) |
|---|---|
| Pegfilgrastim (Neulasta) | 318 |
| Placebo | 322 |
Death from any cause through the end of the follow-up period (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 47 |
| Placebo | 49 |
5 reviews available for fluorouracil and Fever
| Article | Year |
|---|---|
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Epirubicin | 2012 |
Systemic toxicity from occlusive therapy with topical 5-fluorouracil: a case report and review of the literature.
Topics: Abdominal Pain; Administration, Cutaneous; Antimetabolites, Antineoplastic; Chills; Diarrhea; Drug E | 2012 |
Successful treatment of radiofrequency-induced biliary lesions by interventional endoscopic retrograde cholangiography (ERC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma, Hepatocellula | 2003 |
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biotransformation; Deoxyuracil Nucleotides; Diarrhea; Di | 2004 |
Modulation of fluorouracil toxicity with uridine.
Topics: Administration, Oral; Animals; Bone Marrow; Drug Administration Schedule; Fever; Fluorouracil; Human | 1992 |
18 trials available for fluorouracil and Fever
| Article | Year |
|---|---|
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Stud | 2009 |
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cycloph | 2010 |
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2012 |
[Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2003 |
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2004 |
[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer].
Topics: Adjuvants, Immunologic; Adult; Aged; Asthenia; CD4-Positive T-Lymphocytes; Chemoembolization, Therap | 2007 |
[Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Dizziness; Dru | 1995 |
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1993 |
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colon | 1997 |
Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial.
Topics: Abdominal Pain; Adult; Aged; Alkaline Phosphatase; Angiography; Antimetabolites, Antineoplastic; Ant | 1997 |
Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ciprofloxac | 1999 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; | 2000 |
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chills; Combined Moda | 2001 |
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2002 |
24 other studies available for fluorouracil and Fever
| Article | Year |
|---|---|
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fev | 2022 |
Prophylactic piperacillin administration in pediatric patients with solid tumors following different intensities of chemotherapy.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain | 2020 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2014 |
Role of iron oxide core of polymeric nanoparticles in the thermosensitivity of colon cancer cell line HT-29.
Topics: Colonic Neoplasms; Comet Assay; Drug Carriers; Ferric Compounds; Fever; Fluorouracil; HT29 Cells; Hu | 2015 |
[Individualized therapy of synchronous ovarian and colon cancers with lymph].
Topics: Abdominal Pain; Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; | 2015 |
A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antimetabolites, Antineoplastic; Deoxycytidine; Feasibilit | 2016 |
Episodic fevers as a novel feature of the carcinoid syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fever; Fluorouracil; Humans; Male; Malignant Carcino | 2008 |
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; De | 2011 |
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Fema | 2012 |
Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2012 |
Early evaluation for treatment efficacy of 5-fluorouracil and hyperthermia on HCT-116 colon cancer cells by fluorine-18-fluorodeoxyglucose uptake.
Topics: Apoptosis; Cell Proliferation; Colonic Neoplasms; Fever; Fluorodeoxyglucose F18; Fluorouracil; HCT11 | 2012 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carb | 2012 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Topics: Alopecia; Antimetabolites, Antineoplastic; Area Under Curve; Diarrhea; Drug Eruptions; Female; Fever | 2002 |
[Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients].
Topics: Adult; Aged; Analgesia, Epidural; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intraveno | 2006 |
The effects of total-body hyperthermia combined with anticancer drugs on immunity in advanced cancer patients.
Topics: Adult; Antineoplastic Agents; Complement System Proteins; Cyclophosphamide; Doxorubicin; Female; Fev | 1983 |
Multi-chemothermoimmunotherapy for human colon adenocarcinoma in vitro.
Topics: Adenocarcinoma; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carbop | 1996 |
Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bre | 1995 |
p53 gene mutation is not directly related to tumoricidal effects of preoperative radiochemohyperthermia therapy for rectal cancers.
Topics: Alleles; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, | 1996 |
Aztreonam plus piperacillin--empiric treatment of neutropenic fever in gynecology-oncology patients receiving cisplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aztreonam; Bacterial | 1998 |
The effect of hyperthermia on micronucleus induction by mutagens in mice.
Topics: Alkylating Agents; Animals; Antimetabolites; Cell Nucleus; Colchicine; Cross-Linking Reagents; Cyclo | 1999 |
Idiosyncratic reaction after oxaliplatin infusion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chills; Fever; Fluorouracil; | 2001 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |